KR102582602B1 - 효능 검정 - Google Patents

효능 검정 Download PDF

Info

Publication number
KR102582602B1
KR102582602B1 KR1020177034098A KR20177034098A KR102582602B1 KR 102582602 B1 KR102582602 B1 KR 102582602B1 KR 1020177034098 A KR1020177034098 A KR 1020177034098A KR 20177034098 A KR20177034098 A KR 20177034098A KR 102582602 B1 KR102582602 B1 KR 102582602B1
Authority
KR
South Korea
Prior art keywords
cells
tgfβ1
mpc
culture medium
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177034098A
Other languages
English (en)
Korean (ko)
Other versions
KR20180041621A (ko
Inventor
폴 시몬스
콜비 수이레
피오나 씨
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901605A external-priority patent/AU2015901605A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Priority to KR1020237032315A priority Critical patent/KR102885856B1/ko
Publication of KR20180041621A publication Critical patent/KR20180041621A/ko
Application granted granted Critical
Publication of KR102582602B1 publication Critical patent/KR102582602B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
KR1020177034098A 2015-05-05 2016-05-04 효능 검정 Active KR102582602B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237032315A KR102885856B1 (ko) 2015-05-05 2016-05-04 효능 검정

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901605 2015-05-05
AU2015901605A AU2015901605A0 (en) 2015-05-05 Potency assay
PCT/EP2016/060049 WO2016177805A1 (en) 2015-05-05 2016-05-04 Potency assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032315A Division KR102885856B1 (ko) 2015-05-05 2016-05-04 효능 검정

Publications (2)

Publication Number Publication Date
KR20180041621A KR20180041621A (ko) 2018-04-24
KR102582602B1 true KR102582602B1 (ko) 2023-09-25

Family

ID=56087237

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177034098A Active KR102582602B1 (ko) 2015-05-05 2016-05-04 효능 검정
KR1020237032315A Active KR102885856B1 (ko) 2015-05-05 2016-05-04 효능 검정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237032315A Active KR102885856B1 (ko) 2015-05-05 2016-05-04 효능 검정

Country Status (9)

Country Link
US (3) US11795435B2 (enExample)
EP (2) EP4015624B1 (enExample)
JP (3) JP6797833B2 (enExample)
KR (2) KR102582602B1 (enExample)
CN (2) CN107771220B (enExample)
AU (3) AU2016258980B2 (enExample)
CA (1) CA2984987C (enExample)
ES (2) ES2911266T3 (enExample)
WO (1) WO2016177805A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR102506822B1 (ko) * 2018-09-20 2023-03-06 시토스핀, 에스.엘. 기능적 중간엽 줄기 세포의 농축된 집단을 수득하는 방법, 이의 수득된 세포 및 이를 포함하는 조성물
WO2020141473A1 (en) * 2019-01-02 2020-07-09 Mesoblast International Sárl Method for treating lower back pain
US20230221303A1 (en) * 2020-04-20 2023-07-13 Longeveron Inc. Potency assay
EP4641205A1 (en) * 2022-12-23 2025-10-29 Kangstem Biotech Co., Ltd. Method for selecting stem cells with enhanced cartilage differentiation capability and cell therapy product comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011196840A (ja) * 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU680921B2 (en) 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
CA2360044A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
WO2001097872A1 (en) 2000-06-22 2001-12-27 Austin Sam L Bioadhesive compositions and methods of preparation and use
AU2002331408B2 (en) 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
AU2003302132B2 (en) 2002-11-21 2008-02-21 Inverness Medical Switzerland Gmbh Bodily fluid markers of tissue hypoxia
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
KR100802011B1 (ko) 2005-08-10 2008-02-12 인하대학교 산학협력단 층분리배양법을 이용한 골수에서의 중간엽 줄기세포분리방법
CN103857788A (zh) * 2011-10-11 2014-06-11 骨治疗公司 生长和分化因子8(gdf-8)的用途
EP2997047B1 (en) 2013-05-16 2021-04-28 Agency For Science, Technology And Research Heparan sulphates
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
CN103990181B (zh) * 2014-05-26 2015-07-08 中国人民解放军第四军医大学 一种具有诱导活性微载体-细胞复合物的制备方法及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011196840A (ja) * 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.Cao et al., The Spine Journal, Vol. 15, 2015, pp. 530-538.*
Kyurkchive et al., World Journal of Stem Cells, Vol. 6, No. 5, 2014, pp. 552-570.
L.Wen et al., PLOS ONE, Vol. 9, No. 7, 2014.

Also Published As

Publication number Publication date
CA2984987C (en) 2023-10-10
AU2016258980A1 (en) 2017-11-23
JP7754893B2 (ja) 2025-10-15
EP3292199B1 (en) 2022-01-12
JP7335222B2 (ja) 2023-08-29
JP6797833B2 (ja) 2020-12-09
US20240409898A1 (en) 2024-12-12
BR112017023660A2 (pt) 2018-07-17
US20240076621A1 (en) 2024-03-07
KR20230140604A (ko) 2023-10-06
CA2984987A1 (en) 2016-11-10
WO2016177805A1 (en) 2016-11-10
JP2018517900A (ja) 2018-07-05
AU2022203140A1 (en) 2022-06-02
EP4015624B1 (en) 2025-02-19
JP2021036892A (ja) 2021-03-11
US20200140822A1 (en) 2020-05-07
EP4015624A1 (en) 2022-06-22
CN107771220B (zh) 2022-07-05
CN107771220A (zh) 2018-03-06
JP2023159260A (ja) 2023-10-31
HK1247236A1 (zh) 2018-09-21
AU2025205043A1 (en) 2025-07-24
EP3292199A1 (en) 2018-03-14
AU2016258980B2 (en) 2022-02-17
KR102885856B1 (ko) 2025-11-14
CN115141872A (zh) 2022-10-04
KR20180041621A (ko) 2018-04-24
ES2911266T3 (es) 2022-05-18
US11795435B2 (en) 2023-10-24
ES3018944T3 (en) 2025-05-19
AU2022203140B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
AU2022203140B2 (en) Potency assay
Machova Urdzikova et al. Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat
US20220143097A1 (en) Method for treating lower back pain
Clements et al. Modulation of mesenchymal stem cell genotype and phenotype by extracellular matrix proteins
Bohlouli et al. Tissue buccal fat pad–stromal vascular fraction as a safe source in maxillofacial bone regeneration: A clinical pilot study
Labusca et al. Isolation and phenotypic characterisation of stem cells from late stage osteoarthritic mesenchymal tissues
HK1247236B (en) Potency assay
BR112017023660B1 (pt) Método para selecionar células precursoras de linhagem mesenquimal ou células-tronco humanas, composições e uso das mesmas
Åkerlund et al. Prevention and treatment of bone and cartilage damage or disease
Hofer Traumatized muscle-derived multipotent progenitor cells: Pro-angiogenic activity, promotion of nerve growth, and osteogenic differentiation
Beaumont Dental pulp stem cells and leukocyte-and platelet-rich fibrin as candidate therapies for articular cartilage and tendon repair
Yonas Hambissa Characterization of the cell secretomes from undifferentiated and chondro-induced stem cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210421

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221104

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230622

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230920

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230921

End annual number: 3

Start annual number: 1

PG1601 Publication of registration